Genmab — Maj 2024
-
many of them are definitely not up to date. maybe a bit of sense is coming to the stock. but still grossly undervalued. God
weekend -
https://finance.yahoo.com/news/genmab-nasdaq-gmab-q1-2024-163845385.html Transcript fra i går
-
Godmorgen @solsen 1600. Problemet med analytiker kursmål er at vi for det meste ikke ved hvad de har indregnet i deres mål med mindre man har adgang til hele analysen som der generelt kan være meget forskel på fra 1 side til 30 sider. Hvor meget renten vægter o.s.v. Nogle analytikere ved en del om Genmab og andre meget lidt. -
Rome lung cancer summit
https://twitter.com/StephenVLiu/status/1787396191535112279/photo/2 -
here tisotumab mentioned as NSCLC drug, doubt it , but who knows
https://twitter.com/StephenVLiu/status/1787419518131654815/photo/2 -
Hvis I har en LinkedIn profil, vil jeg anbefale at følge Claus Johansen. Han har mange gode indlæg om sundhedsaktier, deriblandt Genmab
-
https://investors.biontech.de/static-files/c8ca4858-2a59-45ab-bc43-6b1df6e3e784 biontech Q1 '24 presentation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind